Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients

BBA Clinical

Volumn 3, Issue , 2015, Pages 141-145

  Goh, George Boon Bee ^a   Pagadala, Mangesh R ^a   Dasarathy, Jaividhya ^c   Unalp Arida, Aynur ^d   Sargent, Ruth ^a   Hawkins, Carol ^b   Sourianarayanane, Achuthan ^a   Khiyami, Amer ^b   Yerian, Lisa ^a   Pai, Rish K ^a   Dasarathy, Srinivasan ^a   McCullough, Arthur J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Department of MetroHealth Medical Center ^*  (United States)

^c MetroHealth Medical Center   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Diabetic; NAFLD; NAFLD fibrosis score; Non diabetic

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIVER BIOPSY; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM;

EID: 84961290966     PISSN: 22146474     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbacli.2014.09.001     Document Type: Article

References (40)

1. Marchesini G., Bugianesi E., Forlani G., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37(4):917-923. 10.1053/jhep.2003.50161.
2. Chalasani N., Younossi Z., Lavine J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55(6):2005-2023. 10.1002/hep.25762.
3. Musso G., Gambino R., Cassader M., Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann. Med. 2011, 43(8):617-649. 10.3109/07853890.2010.518623.
4. Younossi Z.M., Reyes M.J., Mishra A., Mehta R., Henry L. Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. Aliment. Pharmacol. Ther. 2014, 39(1):3-14. 10.1111/apt.12543.
5. Bugianesi E., McCullough A.J., Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005, 42(5):987-1000. 10.1002/hep.20920.
6. El-Serag H.B., Tran T., Everhart J.E. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004, 126(2):460-468.
7. Hossain N., Afendy A., Stepanova M., et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2009, 7(11):1224-1229. (9 e1-2). 10.1016/j.cgh.2009.06.007.
8. Neuschwander-Tetri B.A., Clark J.M., Bass N.M., et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010, 52(3):913-924. 10.1002/hep.23784.
9. Loomba R., Abraham M., Unalp A., et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012, 56(3):943-951. 10.1002/hep.25772.
10. Younossi Z.M., Gramlich T., Matteoni C.A., Boparai N., McCullough A.J. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin. Gastroenterol. Hepatol. 2004, 2(3):262-265.
11. Dixon J.B., Bhathal P.S., O'Brien P.E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001, 121(1):91-100.
12. Gholam P.M., Flancbaum L., Machan J.T., Charney D.A., Kotler D.P. Nonalcoholic fatty liver disease in severely obese subjects. Am. J. Gastroenterol. 2007, 102(2):399-408. 10.1111/j.1572-0241.2006.01041.x.
13. Harrison S.A., Oliver D., Arnold H.L., Gogia S., Neuschwander-Tetri B.A. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008, 57(10):1441-1447. 10.1136/gut.2007.146019.
14. Angulo P., Hui J.M., Marchesini G., et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007, 45(4):846-854. 10.1002/hep.21496.
15. McPherson S., Anstee Q.M., Henderson E., Day C.P., Burt A.D. Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?. Eur. J. Gastroenterol. Hepatol. 2013, 25(6):652-658. 10.1097/MEG.0b013e32835d72cf.
16. American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes Care 2013, 36(Suppl. 1):S67-S74. 10.2337/dc13-S067.
17. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42(6):1206-1252. 10.1161/01.HYP.0000107251.49515.c2.
18. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41(6):1313-1321. 10.1002/hep.20701.
19. Brunt E.M., Kleiner D.E., Wilson L.A., et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011, 53(3):810-820. 10.1002/hep.24127.
20. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28(7):412-419.
21. McPherson S., Stewart S.F., Henderson E., Burt A.D., Day C.P. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010, 59(9):1265-1269. 10.1136/gut.2010.216077.
22. Nakahara T., Hyogo H., Yoneda M., et al. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J. Gastroenterol. 2013, 10.1007/s00535-013-0911-1.
23. Argo C.K., Caldwell S.H. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin. Liver Dis. 2009, 13(4):511-531. 10.1016/j.cld.2009.07.005.
24. Adams L.A., Sanderson S., Lindor K.D., Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J. Hepatol. 2005, 42(1):132-138. 10.1016/j.jhep.2004.09.012.
25. Adams L.A., Harmsen S., St Sauver J.L., et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am. J. Gastroenterol. 2010, 105(7):1567-1573. 10.1038/ajg.2010.18.
26. Ekstedt M., Franzen L.E., Mathiesen U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44(4):865-873. 10.1002/hep.21327.
27. Soderberg C., Stal P., Askling J., et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010, 51(2):595-602. 10.1002/hep.23314.
28. Matteoni C.A., Younossi Z.M., Gramlich T., et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116(6):1413-1419.
29. Pagadala M.R., McCullough A.J. The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis. Clin. Liver Dis. 2012, 16(3):487-504. 10.1016/j.cld.2012.05.006.
30. Yeh M.M., Brunt E.M. Pathology of nonalcoholic fatty liver disease. Am. J. Clin. Pathol. 2007, 128(5):837-847. 10.1309/RTPM1PY6YGBL2G2R.
31. Brunt E.M. Pathology of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 2010, 7(4):195-203. 10.1038/nrgastro.2010.21.
32. Argo C.K., Northup P.G., Al-Osaimi A.M., Caldwell S.H. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J. Hepatol. 2009, 51(2):371-379. 10.1016/j.jhep.2009.03.019.
33. Giannini E., Botta F., Fasoli A., et al. Progressive liver functional impairment is associated with an increase in AST/ALT ratio. Dig. Dis. Sci. 1999, 44(6):1249-1253.
34. Fan J.G., Zhu J., Li X.J., et al. Fatty liver and the metabolic syndrome among Shanghai adults. J. Gastroenterol. Hepatol. 2005, 20(12):1825-1832. 10.1111/j.1440-1746.2005.04058.x.
35. Tilg H., Moschen A.R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010, 52(5):1836-1846. 10.1002/hep.24001.
36. Peverill W., Powell L.W., Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int. J. Mol. Sci. 2014, 15(5):8591-8638. 10.3390/ijms15058591.
37. Qureshi K., Clements R.H., Abrams G.A. The utility of the "NAFLD fibrosis score" in morbidly obese subjects with NAFLD. Obes. Surg. 2008, 18(3):264-270. 10.1007/s11695-007-9295-8.
38. Wong V.W., Wong G.L., Chim A.M., et al. Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. Am. J. Gastroenterol. 2008, 103(7):1682-1688. 10.1111/j.1572-0241.2008.01933.x.
39. Perez-Gutierrez O.Z., Hernandez-Rocha C., Candia-Balboa R.A., et al. Validation study of systems for noninvasive diagnosis of fibrosis in nonalcoholic fatty liver disease in Latin population. Ann. Hepatol. 2013, 12(3):416-424.
40. Yoneda M., Imajo K., Eguchi Y., et al. Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels. J. Gastroenterol. 2013, 48(9):1051-1060. 10.1007/s00535-012-0704-y.